Literature DB >> 7388735

Management and survival of female breast cancer: results of a national survey by the American College of Surgeons.

T Nemoto, J Vana, R N Bedwani, H W Baker, F H McGregor, G P Murphy.   

Abstract

This is a resume of a Breast Cancer Survey carried out by the American College of Surgeons in 1978. Four hundred and ninety-eight hospitals in 47 states, Washington, D.C., and Puerto Rico participated, contributing a total of 24,136 female patients with histologically confirmed breast cancer. In these patients, five-year cure rates were 60.5% for clinically localized disease and 33.9% for regional disease. Five-year survival rates were 72.8% for localized disease and 49.1% for regional disease. From the 1960's into the early 1970's, there was a gradual shift away from radical mastectomy towards so-called modified radical mastectomy. In a group of patients treated by either radical or modified mastectomies, the axillary nodal status, size of the tumor, and location of the tumor were examined in relation to the prognosis. In the study of number of metastatic nodes in the axilla, there were reduced cure and survival rates in patients with one or more positive nodes as compared to those with negative axillary nodes. With the increase in the number of positive nodes, there was a continuing associated decline in survival and cure. The clinical size of the tumor also correlated well to the prognosis. With the increase in the size of the tumor, there was a gradual increase in the probability of axillary nodal involvement. However, in the group of patients with tumor size smaller than 1 cm, axillary metastasis occurred in 25%. When the axillary nodes were involved, the cure rate in those patients was not significantly better than the rates for those with larger primary tumors in this study. Tumors located in the medial half of the breast were associated with a slightly lower cure rate than those in the lateral half. Young women under 35 years of age had poorer survival and cure rates, although in women 35-44 years of age, the five-year results were comparable to the older group of patients. In blacks, breast cancer was diagnosed in a relatively more advanced stage than in whites. Survival and cure rates were generally lower for blacks, and such lower rates seem to be associated with the relatively advanced stage of the disease.

Entities:  

Mesh:

Year:  1980        PMID: 7388735     DOI: 10.1002/1097-0142(19800615)45:12<2917::aid-cncr2820451203>3.0.co;2-m

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  109 in total

1.  Significance of Flow Cytometric DNA Analysis from Freshly Aspirated Samples.

Authors: 
Journal:  Breast Cancer       Date:  1995-10-31       Impact factor: 4.239

2.  Controversies in the Surgical Management of Operable Breast Cancer.

Authors: 
Journal:  Breast Cancer       Date:  1994-12-30       Impact factor: 4.239

3.  The Nottingham Prognostic Index in primary breast cancer.

Authors:  M H Galea; R W Blamey; C E Elston; I O Ellis
Journal:  Breast Cancer Res Treat       Date:  1992       Impact factor: 4.872

4.  Radical axillary dissection in the staging and treatment of breast cancer.

Authors:  M A Chaudary
Journal:  Ann R Coll Surg Engl       Date:  1992-09       Impact factor: 1.891

5.  Urban black women's perceptions of breast cancer and mammography.

Authors:  J H Price; S M Desmond; S Slenker; D Smith; P W Stewart
Journal:  J Community Health       Date:  1992-08

6.  Prognostic value of proliferative activity in lymph node metastases of patients with breast cancer.

Authors:  P J van Diest; E Matze-Cok; J P Baak
Journal:  J Clin Pathol       Date:  1991-05       Impact factor: 3.411

Review 7.  Node negative breast cancer.

Authors:  S M O'Reilly; M A Richards
Journal:  BMJ       Date:  1990-02-10

8.  Omission of Axillary Lymph Node Dissection is Associated with Inferior Survival in Breast Cancer Patients with Residual N1 Nodal Disease Following Neoadjuvant Chemotherapy.

Authors:  Muayad F Almahariq; Ronald Levitin; Thomas J Quinn; Peter Y Chen; Nayana Dekhne; Sayee Kiran; Amita Desai; Pamela Benitez; Maha S Jawad; Gregory S Gustafson; Joshua T Dilworth
Journal:  Ann Surg Oncol       Date:  2020-07-25       Impact factor: 5.344

Review 9.  Management of the Axilla after Neoadjuvant Systemic Therapy.

Authors:  Trista J Stankowski-Drengler; Heather B Neuman
Journal:  Curr Treat Options Oncol       Date:  2020-05-27

Review 10.  Epirubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cancer chemotherapy.

Authors:  G L Plosker; D Faulds
Journal:  Drugs       Date:  1993-05       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.